Racial and Ethnic Changes in Heroin Injection in the United States: Implications for the HIV/AIDS Epidemic

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2008 Feb 5

PMID 18242879

Citations 45

Authors

Dita Broz

Lawrence J Ouellet

Affiliations

Soon will be listed here.

Abstract

Background: Racial/ethnic differences in drug injection prevalence contribute to disparities in HIV infection rates in the US between Whites, Blacks and Hispanics. We examine trends in the demographic characteristics of heroin injection drug users (IDUs) that may impact future HIV rates.

Methods: Descriptive analyses were conducted of (1) the national Treatment Episode Data Set for 1992-2004 and of the 2002-2004 baseline data from (2) CIDUS-III, a 5-city study that recruited 3285 young IDUs, and (3) NIHU-HIT, a Chicago study of 647 young noninjecting heroin users.

Results: Between 1992 and 2004, heroin was the injected drug most often reported at admission to drug treatment. During this period, the proportion of admissions reporting injection declined 44% among Blacks but only 14% for Whites. The peak age for heroin IDUs in treatment increased 10 years for Blacks while declining over 10 years for Whites. CIDUS-III enrolled about 8 times more White (64%) than Black (8%) young IDUs despite recruiting two-thirds of the sample in cities where Blacks constituted 27-64% of the population. Blacks comprised 53% of noninjecting heroin users in the Chicago NIHU-HIT, but only 2% of Chicago's CIDUS-III sample of heroin IDUs. Among current noninjecting heroin users, Whites were more likely than Blacks to have ever injected (X(d.f.=1)(2)=17.1, p<0.001). Qualitative data supported greater resistance to injection among young Blacks than Whites.

Conclusions: Among heroin users, young Blacks are resisting injection while young Whites exhibit the opposite tendency. New research should investigate reasons for this trend and its impact on the HIV epidemic and future service needs.

Citing Articles

Fentanyl Exposure and Detection Strategies Utilized by Clinical Trial Participants Seeking Linkage to Opioid Use Disorder Treatment at a Syringe Service Program.

Watson D, Ray B, Phalen P, Clarke S, Taylor L, Swartz J J Med Toxicol. 2023; 20(1):13-21.

PMID: 38048033 PMC: 10774457. DOI: 10.1007/s13181-023-00979-7.

Variation in HIV Transmission Behaviors Among People Who Use Drugs in Rural US Communities.

Jenkins W, Friedman S, Hurt C, Korthuis P, Feinberg J, Del Toro-Mejias L JAMA Netw Open. 2023; 6(8):e2330225.

PMID: 37603331 PMC: 10442709. DOI: 10.1001/jamanetworkopen.2023.30225.

Context and correlates of providing assistance with someone's first injection in the AIDS linked to the IntraVenous Experience cohort, Baltimore, MD.

Gicquelais R, Astemborski J, Werb D, Kirk G, Mehta S, Genberg B Drug Alcohol Depend. 2023; 250:110909.

PMID: 37517262 PMC: 10529208. DOI: 10.1016/j.drugalcdep.2023.110909.

Injurious Fall in an Elderly Chronic Heroin Addict During a Syncopal Episode.

Maita E, Bodavula G, Bello A, Chehade R, Kuchipudi S Cureus. 2023; 15(4):e37736.

PMID: 37214010 PMC: 10192483. DOI: 10.7759/cureus.37736.

People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination.

Boodram B, Mackesy-Amiti M, Khanna A, Brickman B, Dahari H, Ozik J PLoS One. 2022; 17(1):e0248850.

PMID: 35020725 PMC: 8754317. DOI: 10.1371/journal.pone.0248850.

References

Dewhurst J . Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence. AIDS Care. 2016; 22(3):397. DOI: 10.1080/09540120903193757. View

Lansky A, Abdul-Quader A, Cribbin M, Hall T, Finlayson T, Garfein R . Developing an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System. Public Health Rep. 2007; 122 Suppl 1:48-55. PMC: 1804107. DOI: 10.1177/00333549071220S108. View

Gibson D, Flynn N, Perales D . Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001; 15(11):1329-41. DOI: 10.1097/00002030-200107270-00002. View

Layden-Almer J, Ribeiro R, Wiley T, Perelson A, Layden T . Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003; 37(6):1343-50. DOI: 10.1053/jhep.2003.50217. View

Garfein R, Doherty M, Monterroso E, Thomas D, Nelson K, Vlahov D . Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18 Suppl 1:S11-9. DOI: 10.1097/00042560-199802001-00004. View

Perlis T, Des Jarlais D, Friedman S, Arasteh K, Turner C . Audio-computerized self-interviewing versus face-to-face interviewing for research data collection at drug abuse treatment programs. Addiction. 2004; 99(7):885-96. DOI: 10.1111/j.1360-0443.2004.00740.x. View

Armstrong G, Wasley A, Simard E, McQuillan G, Kuhnert W, Alter M . The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10):705-14. DOI: 10.7326/0003-4819-144-10-200605160-00004. View

Kral A, Lorvick J, Edlin B . Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr. 2000; 24(2):162-7. DOI: 10.1097/00126334-200006010-00011. View

Hughes P, Rieche O . Heroin epidemics revisited. Epidemiol Rev. 1995; 17(1):66-73. DOI: 10.1093/oxfordjournals.epirev.a036186. View

10.

ODonnell J, Jones J . Diffusion of the intravenous technique among narcotic addicts in the United States. J Health Soc Behav. 1968; 9(2):120-30. View

11.

Rittenhouse J . The epidemiology of heroin and other narcotics: selected themes of the discussion. NIDA Res Monogr. 1977; 16:15-22. View

12.

Hughes P, BARKER N, Crawford G, Jaffe J . The natural history of a heroin epidemic. Am J Public Health. 1972; 62(7):995-1001. PMC: 1530426. DOI: 10.2105/ajph.62.7.995. View

13.

Friedman S, Chapman T, Perlis T, Rockwell R, Paone D, Sotheran J . Similarities and differences by race/ethnicity in changes of HIV seroprevalence and related behaviors among drug injectors in New York City, 1991-1996. J Acquir Immune Defic Syndr. 1999; 22(1):83-91. DOI: 10.1097/00042560-199909010-00011. View

14.

Strang J, Griffiths P, Gossop M . Heroin in the United Kingdom: different forms, different origins, and the relationship to different routes of administration. Drug Alcohol Rev. 2005; 16(4):329-37. DOI: 10.1080/09595239700186711. View

15.

Novelli L, Sherman S, Havens J, Strathdee S, Sapun M . Circumstances surrounding the first injection experience and their association with future syringe sharing behaviors in young urban injection drug users. Drug Alcohol Depend. 2005; 77(3):303-9. DOI: 10.1016/j.drugalcdep.2004.08.021. View

16.

Thorpe L, Bailey S, Huo D, Monterroso E, Ouellet L . Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). J Acquir Immune Defic Syndr. 2001; 27(1):71-8. DOI: 10.1097/00126334-200105010-00012. View

17.

Fuller C, Vlahov D, Ompad D, Shah N, Arria A, Strathdee S . High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: a case-control study. Drug Alcohol Depend. 2002; 66(2):189-98. DOI: 10.1016/s0376-8716(01)00200-9. View

18.

Golub A, Johnson B . Cohort changes in illegal drug use among arrestees in Manhattan: from the Heroin Injection Generation to the Blunts Generation. Subst Use Misuse. 1999; 34(13):1733-63. DOI: 10.3109/10826089909039425. View

19.

Adair E, Craddock S, Miller H, Turner C . Assessing consistency of responses to questions on cocaine use. Addiction. 1995; 90(11):1497-502. DOI: 10.1046/j.1360-0443.1995.901114978.x. View

20.

Lankenau S, Sanders B, Jackson Bloom J, Hathazi D, Alarcon E, Tortu S . First injection of ketamine among young injection drug users (IDUs) in three U.S. cities. Drug Alcohol Depend. 2006; 87(2-3):183-93. PMC: 1852477. DOI: 10.1016/j.drugalcdep.2006.08.015. View